Young David 4

What Happened David Young, President of Research & Development and a director at Processa Pharmaceuticals, purchased 1,786 shares in an open-market transaction on 2026-05-29 at $2.57 per share, for a total cost of $4,590. The transaction is coded P (purchase) and was reported on a Form 4 filed 2026-06-01. Purchases by insiders are often watched closely by investors as potentially more informative than routine sales, but they do not by themselves prove future company performance.

Key Details

• Transaction date: 2026-05-29
• Filing (Form 4) date: 2026-06-01 (appears timely under the SEC two-business-day rule)
• Transaction type/code: Open-market purchase (P)
• Price per share: $2.57
• Shares acquired: 1,786
• Total value: $4,590
• Shares owned after transaction: Not specified in the information provided; see the full Form 4 (Accession 0000897069-26-001295) for the “Amount Owned Following Reported Transaction” field
• Footnotes/plan: No 10b5-1 plan, tax withholding, or other footnotes were indicated in the provided summary

Context This is a small-dollar purchase by an officer/director rather than a large institutional transaction. It’s factual insider buying information — useful to monitor alongside other filings and company fundamentals but not definitive on its own. Refer to the filed Form 4 for full details.